First-Cycle Approval Rate Already High; Can PDUFA V Actually Boost It?
Executive Summary
FDA official says the rate of approving applications in the first review cycle may not increase much more, even as the new review model, intended to promote more first-cycle approvals, has yet to finish with its inaugural applications.
You may also be interested in...
Let's Get Real – ANDA Approval Likely Takes More Than Two Years, US FDA Says
Office of Generic Drugs Director Kathleen Uhl calls a two-cycle approval timeline a realistic expectation for ANDA approval, but would not say that most ANDAs will fall into the paradigm.
Let's Get Real – ANDA Approval Likely Takes More Than Two Years, US FDA Says
Office of Generic Drugs Director Kathleen Uhl calls a two-cycle approval timeline a realistic expectation for ANDA approval, but would not say that most ANDAs will fall into the paradigm.
What Goes Up … US FDA Expects 2016 NME Approval Total To Come Down
After a record-setting 2015 for new drug approvals, there were not enough applications with user fee goals in 2016 to reach that level again.